SA57 is primarily utilized in research settings as a potent and selective inhibitor of diacylglycerol lipase-alpha (DAGL-α), an enzyme involved in the biosynthesis of endocannabinoids. By inhibiting DAGL-α, SA57 helps in studying the role of endocannabinoids in various physiological and pathological processes, including pain, inflammation, and neurodegenerative diseases. Its application is crucial in preclinical studies to understand the endocannabinoid system's function and to explore potential therapeutic targets for conditions like chronic pain, multiple sclerosis, and Alzheimer's disease. Additionally, SA57 is used to investigate the metabolic pathways of lipid signaling molecules, providing insights into cellular communication and regulatory mechanisms.